Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WXNKG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
JBH-492
|
|||||
| Synonyms |
Anti-CCR7 antibody-drug conjugate - Novartis Pharmaceuticals; JBH 492; JBH-492; JBH492
Click to Show/Hide
|
|||||
| Organization |
Novartis Pharmaceuticals Corp.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 2 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Antibody Name |
A humanized Fc-silenced anti-CCR7 IgG1 antibody
|
Antibody Info | ||||
| Antigen Name |
C-C chemokine receptor type 7 (CCR7)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
